Skip to content

Comparison of safety and efficacy of different doses of remimazolam combined with sufentanil in the assisted sedation of ultrasound-guided nerve block

Comparison of safety and efficacy of different doses of remimazolam combined with sufentanil in the assisted sedation of ultrasound-guided nerve block

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000035555
Enrollment
Unknown
Registered
2020-08-13
Start date
2020-08-14
Completion date
Unknown
Last updated
2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthetic

Interventions

Group A:3mg remimazolam
Group B:4mg Remimazolam
Group C:5mg Remimazolam

Sponsors

Department of Anesthesiology, Anhui Provincial Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients who are scheduled for ultrasound-guided nerve block before anesthesia; 2. Patients with ASA grade I ~ III; 3. Patients aged 18-75 years old; 4. Patients without obvious dyspnea and hypoxemia before operation; 5. Patients with educational level above primary school; 6. Patients with preoperative MMSE score >= 23; 7. Patients who sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with severe cardiovascular disease ,peripheral neuropathy, central nervous system disease, puncture site infection,coagulation disorder; 2. Patients with mental disorders; 3. BMI >= 35kg/m2 4. Pregnant women; 5. Lactating women; 6. Failure to follow up, drop out of the study due to personal factors, and 7. Patients who are allergic to drugs in this study; 8. History of taking benzodiazepines and other sedative drugs and opioids abuse; 9. Patients with communication disorders.

Design outcomes

Primary

MeasureTime frame
Hemodynamic index;Spo2;modified observer's assessment of alert /sedation;Depth of anesthesia, Nacrotrend;

Secondary

MeasureTime frame
Incidence of hypoxemia;Incidence of injection pain;onset time;awakening time;

Countries

China

Contacts

Public ContactXiao Yimin

Anhui Provincial Cancer Hospital

869813989@qq.com+86 17756974670

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026